TM London Day One
Wednesday, 6th December 2017
09.10 | How to Achieve Predictability in Development and Monitoring of Tumour Microenvironment Directed Therapies?
Frank Schnieders is founder and CEO of Provecs Medical in Hamburg, Germany. He has more than 15 years of experience in biopharmaceutical industry and entrepreneurship. As a biochemist, his focus in more than 20 years of research in the areas of gene therapy, biomedical and clinical research has been the translation of his research into novel treatment options for cancer patients. He authored numerous scientific publications, filed more than 30 patents related to gene and immunotherapy, was dedicated business awards, and is member of CIC, CIMT, SITC. With a PhD in human genetics from the Medical School Hanover, postdoctoral experience in gene therapy and molecular medicine at the Max-Planck-Institute, Berlin, he started his own research group at the University Medical Center in Hamburg-Eppendorf and founded Provecs Medical as a spin-out. In 2016, the first immune-oncology product Immunalon® entered a development and license cooperation with a pharma partner towards clinical testing.